Sotera Health Co

Sotera Health Co has a market capitalization of $4.48 billion and a price-to-earnings ratio of 57.47, indicating a high valuation relative to its earnings. The company's price-to-book ratio of 7.39 suggests that the market is valuing its equity significantly above its book value. The company's liquidity position is characterized by $344.62 million in cash and equivalents, but its long-term debt of $2.24 billion results in a debt-to-equity ratio of 3.69, indicating a high leverage position. In terms of profitability, Sotera Health Co reports a return on equity of 12.86% and a return on assets of 2.39%. These figures are to be compared against the industry's preferred metrics, which typically emphasize high ROE and ROIC for healthcare services firms. The company's operating margin, calculated as operating income of $295.63 million on revenue of $1.16 billion, is 25.41%, which is a strong indicator of operational efficiency. The company's revenue is primarily derived from its diagnostic and clinical trial services, with no specific segment breakdown provided in the available data. Geographically, the company's exposure is not detailed, but the healthcare services industry is generally less sensitive to geographic concentration due to the global nature of its operations. Looking at the growth trajectory, Sotera Health Co's revenue of $1.16 billion reflects a stable performance. Analysts have set a mean price target of $20.83, suggesting a potential upside from the current market price of $15.71. The mean recommendation of 1.73 indicates a generally positive outlook from analysts, with five strong-buy ratings and four buy ratings. The risk assessment for Sotera Health Co highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could pose challenges in maintaining liquidity. However, the low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term. Recent events, including analyst estimates and price targets, indicate a positive sentiment towards the company. The free cash flow of $76.68 million and operating cash flow of $287.20 million support the company's ability to fund operations and reduce debt. However, the capital expenditure of -$138.02 million indicates a reduction in capital spending, which could affect long-term growth.